Author:
Hasanshahi Zahra,Hashempour Ava,Ghasabi Farzane,Moayedi Javad,Musavi Zahra,Dehghani Behzad,Sharafi Heidar,Joulaei Hassan
Abstract
Abstract
Background
NS5A and NS5B proteins of hepatitis C virus (HCV) are the main targets of compounds that directly inhibit HCV infections. However, the emergence of resistance-associated substitutions (RASs) may cause substantial reductions in susceptibility to inhibitors.
Methods
Viral load and genotyping were determined in eighty-seven naïve HCV-infected patients, and the amplified NS5A and NS5B regions were sequenced by Sanger sequencing. In addition, physicochemical properties, structural features, immune epitopes, and inhibitors-protein interactions of sequences were analyzed using several bioinformatics tools.
Results
Several amino acid residue changes were found in NS5A and NS5B proteins; however, we did not find any mutations related to resistance to the treatment in NS5B. Different phosphorylation and few glycosylation sites were assessed. Disulfide bonds were identified in both proteins that had a significant effect on the function and structure of HCV proteins. Applying reliable software to predict B-cell epitopes, 3 and 5 regions were found for NS5A and NS5B, respectively, representing a considerable potential to induce the humoral immune system. Docking analysis determined amino acids involved in the interaction of inhibitors and mentioned proteins may not decrease the drug efficiency.
Conclusions
Strong interactions between inhibitors, NS5A and NS5B proteins and the lack of efficient drug resistance mutations in the analyzed sequences may confirm the remarkable ability of NS5A and NS5B inhibitors to control HCV infection amongst Iranian patients. The results of bioinformatics analysis could unveil all features of both proteins, which can be beneficial for further investigations on HCV drug resistance and designing novel vaccines.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference81 articles.
1. Moayedi J, Hashempour T, Musavi Z, Dehghani B, Hasanshahi Z, Merat S. The predictive factors for favorable outcomes of peginterferon and ribavirin combination therapy in HCV-infected patients. Acta Med Iran. 2020;58(5):214–20.
2. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20(11):2902–12.
3. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem. 2004;279(47):48576–87.
4. Fridell RA, Valera L, Qiu D, Kirk MJ, Wang C, Gao M. Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles. J Virol. 2013;87(4):2320–9.
5. Alborzi AM, Bamdad T, Davoodian P, Hashempoor T, Nejatizadeh AA, Moayedi J. Insights into the role of HCV plus-/minus strand RNA, IFN-γ and IL-29 in relapse outcome in patients infected with HCV. Asian Pac J Allergy Immunol. 2015;33(3):173–81.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献